1. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.
- Author
-
Erman A, Winkler J, Chen-Gal B, Rabinov M, Zelykovski A, Tadjer S, Shmueli J, Levi E, Akbary A, and Rosenfeld JB
- Subjects
- Administration, Oral, Angiotensin II blood, Female, Humans, Kidney Cortex enzymology, Male, Middle Aged, Myocardium enzymology, Ramipril, Reference Values, Renin blood, Surgical Procedures, Operative, Time Factors, Angiotensin-Converting Enzyme Inhibitors pharmacology, Bridged Bicyclo Compounds pharmacology, Peptidyl-Dipeptidase A metabolism
- Abstract
Studies in animal models have indicated that ramipril is a potent inhibitor of angiotensin converting enzyme (ACE) in serum and tissue. In our study, the normal range of ACE activity and the inhibitory effect of short-term oral administration of ramipril on ACE activity in human serum and tissue samples of renal cortex, heart and blood vessels were determined. ACE activity in the renal cortex (125.2 +/- 11.5 nmol/mg per min) was greater than 600 times that of the heart (0.20 +/- 0.01 nmol/mg per min), greater than 500 times that of the veins (0.23 +/- 0.09 nmol/mg per min) and greater than 150 times that of the arteries (0.80 +/- 0.23 nmol/mg per min). ACE activity in the renal cortex and arteries 2 h after last dosing was almost completely inhibited by ramipril whereas ACE activity in the veins and heart was inhibited to a lesser extent. Our results demonstrate in man, for the first time, an inhibition of tissue ACE following short-term oral treatment with an ACE inhibitor.
- Published
- 1991
- Full Text
- View/download PDF